Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for <font color="blue">advanced_1</font> <font color="blue">nasopharyngeal_1</font> <font color="blue">carcinoma_1</font> <font color="blue">:_1</font> positive effect on <font color="blue">overall_2</font> <font color="blue">and_2</font> <font color="blue">progression_2</font> <font color="blue">-_2</font> <font color="blue">free_2</font> <font color="blue">survival_2</font> <font color="blue">._2</font> <font color="blue">
<br>
<br>_1</font> PURPOSE <font color="blue">Nasopharyngeal_1</font> <font color="blue">carcinoma_1</font> ( NPC ) is a radiosensitive and chemosensitive tumor . This randomized phase III trial <font color="blue">compared_1</font> concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone in patients with advanced NPC . 
<br> PATIENTS AND METHODS From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC were randomly allocated into two arms . Similar dosage and fractionation of RT was administered in both arms . The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg / m(2)/d plus fluorouracil 400 mg / m(2)/d by 96-hour continuous infusion during the weeks 1 and 5 of RT . <font color="blue">Survival_4</font> <font color="blue">analysis_4</font> <font color="blue">was_1</font> <font color="blue">estimated_1</font> <font color="blue">by_1</font> <font color="blue">the_1</font> <font color="blue">Kaplan_1</font> <font color="blue">-_1</font> <font color="blue">Meier_1</font> <font color="blue">method_1</font> <font color="blue">and_1</font> <font color="blue">compared_1</font> <font color="blue">by_1</font> <font color="blue">the_1</font> <font color="blue">log_1</font> <font color="blue">-_1</font> <font color="blue">rank_1</font> <font color="blue">test_1</font> <font color="blue">._1</font> <font color="blue">
<br>_1</font> RESULTS <font color="blue">Baseline_1</font> <font color="blue">patient_1</font> <font color="blue">characteristics_1</font> were comparable in both arms . After a median follow - up of 65 months , 26.2% ( 37 of 141 ) and 46.2% ( 66 of 143 ) of patients developed <font color="blue">tumor_1</font> <font color="blue">relapse_1</font> in the CCRT and RT - alone groups , respectively . <font color="blue">The_1</font> <font color="blue">5-year_2</font> <font color="blue">overall_4</font> <font color="blue">survival_4</font> <font color="blue">rates_3</font> were 72.3% for the CCRT arm and 54.2% for the RT - only arm ( P = .0022 ) . <font color="blue">The_1</font> <font color="blue">5-year_2</font> <font color="blue">progression_4</font> <font color="blue">-_4</font> <font color="blue">free_4</font> <font color="blue">survival_4</font> <font color="blue">rates_3</font> were 71.6% for the CCRT group compared with 53.0% for the RT - only group ( P = .0012 ) . Although <font color="blue">significantly_2</font> <font color="blue">more_2</font> <font color="blue">toxicity_4</font> <font color="blue">was_1</font> <font color="blue">noted_1</font> in the CCRT arm , including <font color="blue">leukopenia_2</font> <font color="blue">and_2</font> <font color="blue">emesis_2</font> <font color="blue">,_2</font> <font color="blue">compliance_1</font> with the combined treatment was good . The second cycle of concurrent chemotherapy was refused by nine patients and was delayed for > or = 1 week for another nine patients . There were <font color="blue">no_3</font> <font color="blue">treatment_2</font> <font color="blue">-_2</font> <font color="blue">related_2</font> <font color="blue">deaths_3</font> in either arm . 
<br> CONCLUSION We conclude that <font color="blue">CCRT_1</font> <font color="blue">is_1</font> <font color="blue">superior_2</font> <font color="blue">to_1</font> <font color="blue">RT_1</font> alone for patients with advanced NPC in endemic areas .